Effect of SAMe Treatment on Recurrence After Radical Treatment of Primary Hepatic Carcinoma

A Randomized Controlled Study on the Effect of S-Adenosyl Methionine Treatment on Anti-tumor Recurrence After Radical Treatment of Primary Hepatic Carcinoma

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03178929

Enrollment

207

Registered

2017-06-07

Start date

2017-07-01

Completion date

2020-08-31

Last updated

2017-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Liver Cancer

Brief summary

The aim of this study is to explore the effect of SAMe on recurrence after radical treatment of Primary liver cancer.

Detailed description

Primary liver cancer is now a major health problem. In the worldwide, PLC is the fifth most common cancer in male, the seventh in female, and has the second highest rate to cause death for men . Although the recent advances in treatment of Primary liver cancer have significantly improved the prognosis of patients with Primary liver cancer, the overall survival rate is still unsatisfactory. One of the reasons for the poor prognosis of Primary liver cancer is its high rate of recurrence. Anti-relapse treatment remains a pressing work to do. In recent years, some study reported that SAMe had an impact on promoting apoptosis and inhibiting the growth on breast cancer, colon cancer, gastric cancer and liver cancer in vitro and vivo. In this study, we aim to examine whether SAMe have an effect on improving patients' recurrence after radical treatment of Primary liver cancer.

Interventions

DRUGS-Adenosyl Methionine

2000mg, po

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient must sign the informed consent prior to the beginning of any study-related procedures; * Patients diagnosed of Primary liver cancer; * BCLC Stage：Stage 0、Stage A; * Accept radical treatment;

Exclusion criteria

* With any other anti-cancer treatment before or after the surgery; * Patients with extrahepatic metastasis; * Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction; * Subjects accepting other trial drugs or participating in other clinical trials; * Female with pregnancy or during the lactation period.

Design outcomes

Primary

Measure	Time frame
Time to tumor recurrence	2 years

Secondary

Measure	Time frame
Overall survival	2 years

Contacts

Primary ContactYin ying Lu, MD

luyinying1973@163.com13301256799

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026